Sarepta Therapeutics discontinues the development of vesleteplirsen (SRP-5051), an exon-skipping antisense oligonucleotide (ASO) for Duchenne muscular dystrophy (DMD).
Sarepta Therapeutics has halted the development of SRP-5051 for Duchenne muscular dystrophy due to safety concerns and the evolving treatment landscape.